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Summary: A radioimmunological method for the sensitive estimation of plasma corticotropin immunoreactivity
(ACTH) using commercially available reagents is presented. The method involves silica extraction of corticotropin
from plasma, desorption with acid protein solution, neutralization and subsequent radioimmunoassay (RIA). [1251]cor-
ticotropin is added as internal standard to the plasma sample. The amounts of corticotropin extractable with silica dif-
fered considerably between the plasma samples of individual subjects. There were marked differences in the affinity
of five different corticotropin standards to the antiserum used. The detection limit of the method was found to be
1.47 pmol/1. Blanks arising in water and in charcoal stripped serum were lower than the detection limit. Precision
and accuracy were within the range commonly achieved for RIA-methods. Morning levels of normal subjects ranged
from 6.5 — 10.9 — 18.5 pmol/1. Hydrocortisone infusion suppressed plasma corticotropin from 12.6 ± 6.4 (S. D.) to
4.4 ±3.1 (S. D.) pmol/1. Infusion of metyrapone increased corticotropin levels from 7.3 ± 4.2 (S. D.) to 15.3 ± 6.0
(S. D.) pmol/1.
Entwicklung eines empfindlichen Radioimmunoassays zur Bestimmung von Corticotropin im Plasma unter Verwen-
dung kommerziell erhältlicher Reagenzien
Zusammenfassung: Es wird eine radioimmunologische Methode zur empfindlichen Bestimmung von Corticotropin
im menschlichen Plasma unter Verwendung kommerziell erhältlicher Reagenzien beschrieben. Die methodischen
Schritte bestehen im einzelnen aus einer Kieselgel-Extraktion von Corticotropin aus Plasma, Desorption mi; einer
sauren Proteinlösung, Neutralisation und abschließendem Radioimmunoassay. [125I]Corticotropin wird als interner
Standard zur Plasmaprobe gegeben. Die an Kieselgel extrahierbaren Corticotropin-Mengen unterscheiden sich signifi-
kant zwischen den Proben verschiedener Individuen. Fünf verschiedene Corticotropin-Standards wiesen deutlich un-
terschiedliche Affinitäten zu dem in der Methode angewandten Antiserum auf. Die Nachweisgrenze der Methode ist
1,47 ± 0,29 (x ± s) pmol/1. Der ,Blank'-Wert in Wasser und in mit Aktivkohle extrahiertem Serum war niedriger als die
Nachweisgrenze. Präzision und Richtigkeit waren in der Größenordnung, die allgemein mit der radioimmunologischen
Technik erreicht wird. Der Normalbereich morgendlicher Corticotropin-Konzentrationen betrug 6,5 - 10,9 - 18,5
pmol/1. Durch eine Infusion von Hydrocortison wurden die Konzentrationen von Corticotropin im Plasma von
12,6 ± 6,9 (x ± s) auf 4,4 ± 3,1 (x ± s) pmol/1 supprimiert. Nach einer Infusion von Metopiron stiegen sie von
7,39 ± 4,2 (x ± s) auf 15,38 ± 6,02 ( ± s) pmol/1 an.
Introduction nous corticotropin-binding proteins in plasma (5). Suffi-
cient sensitivity, which is of special importance for the
Availability of plasma corticotropin radioimmunoassays
 detection of suppressed plasma levels, e.g. in primary
has contributed enormously to the understanding of the hyperadrenocorticism (6), is generally achieved by ex-
pituitary-adrenal axis under physiological and pathplo- tracting corticotropin from greater quantities of plasma
gical conditions (1, 2). A reliable estimation, however, (7-10). In the literature, only a few assays (11,12), in-
has to do justice to several challenges especially inherent
in corticotropin analysis, such as the extremely low phy- —^
siolögical concentrations of corticotropin in blood (3), -
 l} ^  papef was presented in part to the European conference
too rapid destruction of the corticotropin molecule by
 on Biochemical and Instrumental Analysis, München, April
proteolytic enzymes (4), and the presence of endoge- 1978
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eluding a radioimmunoassay (RIA) kit marketed by CIS-
Sorin (13), are reported to be feasible in unextracted
plasma. Although antisera used in these assays exhibit
high affinity to the corticotropin molecule, they are not
able to monitor distinctly suppressed corticotropin va-
lues in plasma. In addition, in these direct assays, poten-
tially interfering binding proteins are ignored, which
may account for anomalous results recently reported
for the RIA kit (14).
The purpose of the present study was to develop an cor-
ticotropin RIA particularly featuring the following
points:
1. to be sufficiently sensitive for the differential diagno-
sis of Cushing's syndrome,
2. to monitor procedural losses of individual samples,
3. to be practicable and easily accessible for routine la-
boratories.
Procedures
Sample preparation
10 ml of blood were drawn in an ice-cooled plastic tube contain-
ing the stabilizer, carefully mixed and centrifuged immediately
at 4 °C. TTie plasma was frozen at -20 °C until analysis. Before
assay, the plasma was thawed and recentrifuged at 8 000 g for
10 min to remove precipitates.
Extraction of corticotropin from plasma
2 ml of plasma were pipetted into a plastic tube, containing 36
Bq of (1^5I]corticotropin (dissolved in 100 ìÀ of barbital buffer
I) and equilibrated for 60 min. After addition of 20 mg of Quso
O32 (suspended in 500 ìÀ of barbital buffer I) to the samples,
the tubes were thoroughly mixed on a rotatory mixer for 3
min. The suspension was centrifuged at 5 000 g for 10 min, the
supernatant decanted and the pellet washed with 3 ml of water.
The pellet was resuspended in 1 ml of the acid bovine serum al-
bumin solution A and thoroughly mixed for 30 min. After centri-
fugation at 8000 g, l ml of the supernatant was carefully trans-
ferred into a plastic tube. At this step, individual procedural losses
were monitored by measuring gamma-radioactivity in the tubes.
Finally, 0.2 ml of 0.525 mol/1 NaOH were added, and 0.5 ml -
duplicates of the complete extraction solution were assayed by
RIA.
Materials and Methods
Reagents and solutions
1-39 Corticotropin (A) (synthetic, human 210 lU/mg) from
CEA, Gif-sur-Yvette (France), purchased from IDW (Frankfurt,
FRG); 1-24 corticotropin (B) (synthetic, 100 lU/mg) from
CIBA (Basel, Switzerland); 1-39 corticotropin (C) (porcine,
160 lU/mg) from Ferring (Kiel, FRG); 1-39 corticotropin (D)
(porcine, grade 1,150 IU/mg)from Sigma (Munich, FRG); 1-39
corticotropin (E) (human) from Amersham (Buckinghamshire,
England). Anti 1-39 corticotropin (porcine) and [l25I]l-39
corticotrooin (porcine) with specific activity of 11.8 GBq/mg
were components of the CIS-Sorin-RIA kit (purchased from
IDW, Frankfurt).
1 mol/1 HC1,1 mol/1 NaOH, EDTA, mercaptoethanol (all analy-
tical grade) from Merck (Darmstadt, FRG); Quso G-32 from Phi-
ladelphia Quartz Co., (Philadelphia, PA, USA); bovine serum al-
bumin from Behring Werke (Marburg, FRG); Dextran T40 from
Pharmacia (Uppsala, Sweden); charcoal Norit A from Serva (Hei-
delberg, FRG); aprotinin (Trasylol®) from Bayer (Leverkusen,
FRG); metyrapone from CIBA (Basel, Switzerland); dexametha-
sone from Ferring (Kiel).
Bovine serum albumin solution A: 2 g of bovine serum albumin
was dissolved in 100 ml of 0.15 mol/1 HC1 and stored at 4 °C
Bovine serum albumin solution B: 100 ml of 0.115 mol/1 HC1
containing 20 g/1 of bovine serum albumin were mixed with 20
ml of 0.525 mol/1 NaOH.
EDTA solution: 5 g of EDTA were dissolved in 100 ml of water.
Stabilizer: for 10 ml of blood, a mixture of 10 mg EDTA (200
ìÀ of the EDTA solution), 4000 KIU of aprotinin (Trasylol®,
200 ìÉ of original solution) and 20 ìÀ of mercaptoethanol were
used.
Corticotropin-free serum (F-serum): 100 ml of normal human
serum was mixed with 5 g of charcoal. After storage overnight
at ambient temperature, aliquots of the mixture were centri-
fuged at 15 000 £ for 20 min and the supernatant was stored at
- 20 °C until used.
Barbital buffer I: 0.02 mol/1 barbital buffer pH 8.6 containing
2 g/1 mercaptoethanol.
Barbital buffer II: 0.07 mol/1 barbital buffer pH 8.6 containing
2 g/1 mercaptoethanoL
Gamma-radioactivity was measured in a Gamma-spectrometer
(Type RI200, Fa. Riedel).
Radioim munpassay
The radioimmunoassay was set up in polystyrene tubes (1.5 ÷
45 mm). The lyophilized reagents, [1^5i]corticotropin, cortico-
tropin-antiserum arid corticotropin-standards, were reconstitu-
ted in distilled water according to the manufacturer's instruc-
tions. The complete pipetting protocol for RIA is outlined in
table 1.
In a pilot study, we evaluated the affinity of different commer-
cially available corticotropin-standards to the antiserum applied.
For this purpose, the corticotropuvstandards B, C and D, which
were provided as crystalline reagents, were dissolved in the
bovine serum albumin solution B and diluted in the same me-
dium up to the appropriate concentration of the standard curve
(each standard dissolved in 500 ìÀ of bovine serum albumin so-
lution B). Corticotropin-free serum (100 ìÀ) was used instead of
the serum standards in these cases. The corticotropin standards
A and Å supplied as serum reagents were set up as outlined in
table 1.
After incubation of the mixture at 4 °C for 24 h, separation of
free and bound corticotropin was achieved by the dextran coa-
ted charcoal method. 10 mg of charcoal suspended in 100 ìÀ of
barbital buffer I were added simultaneously to all RIA tubes.
After mixing and centrifugati n at 2000 g for 10 min, the super-
natants were simultaneously decanted and measured for radioac-
tivity. Evaluation of the RIA data was done by a computer pro-
gram using the spline approximation technique as standard
curve model (15).
Tab. 1. Protocol of the pipetting procedure of the corticotropin
RIA. Values are in ìÉ.
Zero Standard Blank Sample
tubes tubes tubes tubes
Barbital buffer Ð 200
Sample -
Serum standard -
Bovine serum albumin B 500
Corticotropin-free
serum 100
Corticotropin anti-
serum 100
[125I]corticotropin 100
200
—
100
500
_
100
100
300
—
_
500
. 100
100
200
500
__
100
100
,100
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Results
Extraction
The influence of the plasma background of individual
samples on the efficiency of the Quso extraction step
was studied in series of samples from five healthy sub-
jects. From each subject, blood was taken from 8.00 h
to 16.00 h at intervals of one hour. All samples were
processed in one batch. Percentage recoveries of total
[125I]corticotropin remaining in the plasma supernatant
are listed in column 1 of Table"2. No significant differen-
ces are apparent between the samples of one subject. An
equivalent accordance is registered between four sub-
jects, whereas non-extractable corticotropin amounts in
the plasma of subject B.K. differ considerably from
those of the other subjects. The [125I]corticotropin por-
tion remaining in the plasma was removed only to a negli-
gible extent by further (Jjuso extraction. The percentage
recoveries of [125I]corticotropin in the final acid desor-
bant solution (column 2 of Table 2) reflect the corres-
pondent individual differences induced by the first ex-
traction step.
Desorption
The potential loss of protein and acid equivalents from
the bovine serum albumin solution A in the course of the
desorptiori step, which would be of importance for the
incubation medium of the corticotropin standards, was
evaluated by protein estimation and titration of proton
equivalents before and after desorption. While protein
loss was negligible (< 1 %), concentration of protons de-
creased from 0.15 mol/1 to 0.115 ± 0.002 mol/1 (S. D.)
(n=12).
Analytical variables
Sensitivity
In a preliminary study, we established that the CIS anti-
sera applied in the present method provided highest affi-
nity to the human corticotropin molecule when com-
pared with other antisera commercially available to us
(16). The affinity of this antiserum to different commer-
Tab. 2. Percentage recoveries of [1^^I]corticotropin not extrac-
table by Quso G32 from plasma (column 1) and desorbed
from Quso by acid protein solution (column 2). 14 plasma
samples of each subject were studied.
Subject Percentage (1 ? 51J cor- Percentage [12 5I]cor-
ticotropin remaining ticotrppin desorbed
in plasma from Quso G32
mean ± S. D.
R.S.
B.F.
B.K.
M.R.
I.A.
mean
17.73
18.23
37.16
18.39
18.53
22,00
0.66
0.50
1.90
0.49
0.66
mean
60.3
61.8
46.1
62.2
57.7
57.6
± S.D.
2.95
2.30
1.50
2,67
4.40
cially available corticotropin-standards was evaluated in
terms of the mean affinity constants calculated accor-
ding to the Scatchard plot technique (15,17) and in
terms of the molar amounts of standard necessary for
50% displacement of zero bound [125I]corticotropin
radioactivity (tab. 3). While affinity and sensitivity dif-
fered only slightly between the 1-39 corticotropin stan-
dards (standard A, C, D and E), the synthetic 1-24 cor-
ticotropin standard B, however, provided significantly
higher affinity to the antiserum applied if compared with
the 1—39 corticotropin standards. In the present method,
the corticotropin standard A was used throughout. The
detection limit (2 S. D. from zero bound radioactivity)
was found to be 0.71 ± 0.14 (S. D.) fmol corresponding
to a final concentration of 1.47 ± 0.29 (S. D.) pmol/1 if
an average recovery of 57.6% (tab. 2) is taken into ac-
count. The 50% intercept amounted to 6.49 ± 0.93 (S.
D.) fmol corresponding to a final concentration of
13.52 ± 1.93 (S. D.) pmol/1. The lowest standard of the
CIS-RIA kit processed without extraction (according to
the manufacturer's instructions) amounts to 1.3 fmol,
i.e. 13.3 pmol/1 if a 100 ìÀ aliquot of plasma is assayed.
Specificity
There is complete cross reaction between porcine and hu-
man corticotropin (comparison of standards A, C and
D). Further specifications as to the specificity of the
antiserum used are outlined in the manufacturer's in-
structions.
Precision
Ten aliquots of one plasma sample were assayed in one
assay. The coefficient of the intra-assay variability was
found to be 5.67% in a sample of 13.3 pmol/1. Inter-
assay variability was assessed from a lyophilized plasma
pool with a mean of 13.8 pmol/1. Aliquots were recon-
stituted immediately before each assay. Coefficient of
variation was 16.17% (Þ = 8).
Accuracy
Human corticotropin in concentrations of 4.8, 8.55 15.6
and 33.6 pmol/1 was added to corticotropin-free serum.
Tab. 3. Affinity of different corticotropin standards to the anti-
serum used in the present method. Information about
the specific biological activity of standard E was not
available.
A
Affinity constant
(10^1/mol)
50% intercept
(fmol)
50% intercept
(MlU)
3.
4.
4.
.1
,97
69
Â
8
1
.4
.77
0.52
C
1.
7.
D
9
8
5.61
2
5
3
.8
.48
.69
Å
1.2
13.4
—
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Each value was determined in duplicate. The equation
of regression was:
Corticotropin(found) = 1-2 pmol/1 + 0.93 X
corticotropin(added)· Coefficient of correlation was r =
0.998.
Assay blanks
Corticotropin immunoreactivities assessed from 2 ml
samples of water and charcoal-stripped serum respecti-
vely were found to be not significantly different from
zero.
Practicability
The exclusion of any time consuming evaporation step
promotes the present method as adequately practicable
if compared with the classical extracting and concentrat-
ing techniques (17). Preparation of about 40 samples
ready for RIA can be handled by one technician in about
half a day. Total assay is completed by the subsequent
RIA including overnight incubation within another day.
A further considerable advantage of the present method,
as to the interests of a routine laboratory, is represented
by the commercial availability of all reagents.
Corticotropin in normal, stimulated and suppres-
sed states
Reference values
Plasma of 48 apparently healthy persons was collected
between 7.30 h and 10.00 h. The reference range found
was 6.5-10.9-18.5 pmol/1 if a logarithmic distribu-
tion was considered. In table 4, these values are com-
pared with reference values reported in the literature.
Suppression of pituitary activity
Plasma corticotropin concentrations under the condi-
tions of pituitary suppression were studied in five male
Tab. 4. Basal plasma corticotropin levels in man.
Plasma corticotropin
(pmol/1)
Reference
33.5 - 84.4
6.6- 15.5
0 - 17.7
0 -25.5
2.6- 12.2
22.4 ±12.2 (S.D.)
4.8-38.8
1.1- 18.8
3.3-15.5
6.6
22.6 ± 5.9(S.D.)
0 - 15.5
6.9 3.5
4.3 ± 0.3
9.1 ± 7.5
6.5- 18.5
Yalowetzl. 1964(19)
Demur a et aL 1966 (20)
Berson & Yalow 1968 (1)
Orthetal. 1968(3)
London & Greenwood 1968 (21)
Jensen tt2A. 1971 (22)
Matsukunet9Ll97l (23)
Don aid 1971(24)
Besser et al. 1971(25)
Voigt et al. 1971(26)
Galskov 1972 (12)
Croughs el zl 1973(27)
Müller et al 1978(10)
Krieger et al. 1979(28)
ATaoetal. 1979(29)
present method
subjects who received an infusion of hydrocortisone-21-
hemisuccinate (20 mg h"1) from 8.00 h to 13.00 h. Base
levels of plasma corticotrppin at 8.00 h fell from 12.6 ±
6.9 (S. D.) pmol/1 to 4.4 ± 3.1 (S. D.) pmol/1 at 13.00 h.
Stimulation of pituitary activity
Changes of plasma corticotropin after stimulation of pi-
tuitary activity was studied in five male subjects, who
were given an infusion of 800 mg of metyrapone per
hour from 8.00 h to 13.00 h. Plasma corticotropin in-
creased from 7.39 ± 4.2 (S. D.) pmol/1 at 8.00 h to
15.38 ± 6.02 (S. D.) pmol/1 at 16.00 h.
Discussion
The extraction procedure involved in the estimation of
plasma corticotropin hitherto was obviously responsible
for the slow access of this parameter to the routine la-
boratory. The availability of high-affinity antisera as
part of research methods (30) and also of the marketed
CIS-RIA kit inaugurated the direct measurement of cor-
ticotrqpin in plasma, thus inducing widespread assess-
ment of corticotropin in research as well as in routine
laboratories (13, 31).
The data of the present study, however, point out some
problems which have to be considered when practising
direct estimation of plasma corticotropin. Firstly, the
amounts of non-Quso-extractable corticotropin differ-
ing considerably between individual subjects (tab. 2) in-
dicate the presence of corticotropin binding factors in
plasma, which may interfere with the immuriological re-
action of the RIA. These findings, which are in complete
accordance with the observations of Voigt et al. (9) may
account for the anomalous results recently reported by
Howe et al. using the CIS-RIA kit (14). Secondly, the
sensitivity of the direct assay, although sufficient for the
evaluation of elevated plasma levels of corticotropin,
fails to detect plasma corticotropin in subnormal con-
centrations, which is of great interest for the differentia-
tion between primary and secondary forms of disorders
of the pituitary-adrenal axis. Using the direct technique
of the CIS-RIA kit, a detection limit of 10 pmol/1 was
reported byNakao et al. (31), thus covering just normal
values. Therefore, one has to postulate that, for cortico-
tropin estimation, a preceding extraction procedure is
advisable because it reduces interfering plasma factors
(5) and increases total assay sensitivity.
Originally, the present extraction procedure was proces-
sed according to the technique of Voigt et al. (9). Using
theoretical alkaline equivalents for neutralization of the
acid desorption solution, however, the pH of the medium
shifted to higher values than in the corresponding stand^
aid solution, thus causing pH-dependent differences in
binding properties. This artefact was eliminated when
that portion of proton equivalents irreversibly absorbed
on the silica was taken into account.
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The divergency in normal values reported in the literature
(tab. 4) and the problems involved in establishing true
normal ranges have already been widely discussed (18).
Some of these differences are undoubtedly caused by
variations in time of sampling, technique and antisera
used with different specificity to the corticotropin mole-
cule or its fragments. A further reason for divergent va-
lues is the fact that procedural losses are considered in
some cases (2), not in others (9). Furthermore, the dif-
ferent standards used in different laboratories may also
contribute to the problematic comparability of normal
corticotropin values. This point is emphasized by our
findings of different affinities of some commercial cor-
ticotropin standards to the same antiserum, even when
the molecular weight or the biological activity of the
standard is taken into account (tab. 3). Thus, in view of
external quality control, reference values of plasma cor-
ticotropin will still remain a challenge and the establish-
ment of a normal range for each laboratory is strongly
advisable.
The validity of the present method with respect to its
ability to monitor changes of plasma corticotropin in
response to physiological stimuli is adequately documen-
ted. Particularly, it is demonstrated that suppressed va-
lues can be distinctly differentiated from normal values,
thus showing the method to be suitable for the laborato-
ry diagnosis of pituitary-adrenal disorders.
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